SeraCare to Sell RayBiotech Proteomic Products Worldwide

MILFORD, Mass. & NORCROSS, Ga.--(BUSINESS WIRE)--SeraCare Life Sciences, Inc. (NASDAQ: SRLS) and RayBiotech, Inc. announced today that SeraCare will act as an agent for the sale of RayBiotech's full product line of antibody arrays, protein arrays, tissue microarrays and ELISA and EIA kits. The synergy of RayBiotech's innovative portfolio with SeraCare's global reach and expertise in virology, serology, immunology and molecular biology supports the acceleration of biomedical research and product development.

“The partnership with RayBiotech directly supports SeraCare’s growth strategy by expanding our offering of value-added proteomic tools to life sciences researchers around the world”

“The partnership with RayBiotech directly supports SeraCare’s growth strategy by expanding our offering of value-added proteomic tools to life sciences researchers around the world,” said Susan Vogt, President and Chief Executive Officer of SeraCare Life Sciences. “RayBiotech is well regarded in the field of proteomics and their innovative products will benefit our client base while our mutual commitment to science and medicine offers opportunity for clinical advancements.”

“SeraCare is a respected, experienced provider of biological reagents and services to the life science community with a global reach and a motivated sales force,” said Dr. Ray Huang, President of RayBiotech. “By adding SeraCare Life Sciences as an agent, we hope to achieve both increased demand for RayBiotech products in clinical and diagnostic markets and fuel increased opportunity for biomarker discovery and validation.”

RayBiotech first introduced antibody arrays to the market in 2001. Since then, RayBiotech's antibody arrays have been cited in hundreds of top-tier journals such as Cell, Nature, Nature Medicine, PNAS and Lancet. Their extensive selection of arrays includes the largest panel of human, mouse, or rat protein targets available on a single array. RayBiotech offers choices of semi-quantitative screening arrays and quantitative multiplex ELISA arrays, membrane (chemiluminescence detection) and glass slide (fluorescence detection) array platforms and customized array production services. By offering more options for multiplex protein detection than any other company, RayBiotech remains the leader in protein array technologies. The molecular targets detected by RayBiotech's arrays include cytokines, chemokines, growth/angiogenic factors, adipokines, soluble receptors, matrix metalloproteases (MMPs) and their inhibitors.

SeraCare Life Sciences offers the highest quality biologically-based products, cellular immunology products and a broad range of related services to facilitate the discovery, development and production of human diagnostics and therapeutics. SeraCare has a worldwide sales force and an extensive history of service to clinical and research laboratories, biopharmaceutical companies and public health agencies including the National Institutes of Health, the Centers for Disease Control and the U.S. Food and Drug Administration.

About RayBiotech

RayBiotech, the Protein Array Pioneer Company, is committed to developing innovative and reliable technologies for the post-genomic age. Our mission is to provide cutting edge proteomics tools for the advancement of basic and clinical research, the development of better patient diagnostics and the facilitation of drug and biomarker discovery. It is also our mission to provide excellent service and support to our valued customers. RayBiotech is a privately owned company with headquarters in Norcross, GA (suburban Atlanta).

About SeraCare Life Sciences

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly-regulated life sciences industry.

Forward-Looking Statements

This press release contains disclosures that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding our expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these expectations will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, failure to maintain proper inventory levels, availability of financing, covenant limitations in our existing credit facility, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors and changes in the regulatory environment. Many of these factors are beyond our ability to control or predict.